In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $109.00. The company’s ...
Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...
See the top stocks recommended by analysts >> Nektar Therapeutics (NKTR) B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics today and set a price target of $4.00.
Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results